Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,871,912
  • Shares Outstanding, K 109,794
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.20
  • Price/Sales 6.03
  • Price/Cash Flow 16.58
  • Price/Book 3.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 5.82
  • Number of Estimates 1
  • High Estimate 5.82
  • Low Estimate 5.82
  • Prior Year 5.92
  • Growth Rate Est. (year over year) -1.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
325.62 +14.32%
on 11/07/19
373.73 -0.39%
on 12/06/19
+47.77 (+14.72%)
since 11/06/19
3-Month
271.37 +37.18%
on 09/27/19
373.73 -0.39%
on 12/06/19
+80.26 (+27.49%)
since 09/06/19
52-Week
271.37 +37.18%
on 09/27/19
442.00 -15.78%
on 03/04/19
-9.43 (-2.47%)
since 12/06/18

Most Recent Stories

More News
First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell...

REGN : 372.26 (+1.06%)
Regeneron Reports Positive Data on Rare Blood Disorder Drug

Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

NVS : 92.07 (+0.47%)
BAYRY : 19.1200 (-0.26%)
SNY : 46.03 (-0.11%)
REGN : 372.26 (+1.06%)
Why Is Regeneron (REGN) Up 14% Since Last Earnings Report?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

REGN : 372.26 (+1.06%)
Ophthalmic Drugs Market : Global Market Opportunities, Size, Share, Emerging Trends, Technological Innovation And Forecasts To 2025

Global  industry valued approximately USD 23.21 billion in 2016 is anticipated to grow with a healthy growth rate of more than 5.27% over the forecast period 2017-2025. Rising frequencies of eye disorders...

REGN : 372.26 (+1.06%)
SHPG : 179.20 (+4.10%)
VRX.TO : 30.80 (-3.33%)
Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria (PNH), utilizing a weekly subcutaneous...

REGN : 372.26 (+1.06%)
Alnylam Gets Second Product Approval Amid Stiff Competition

Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.

SNY : 46.03 (-0.11%)
ALNY : 123.76 (-0.38%)
MDCO : 84.21 (+0.37%)
REGN : 372.26 (+1.06%)
Esperion's Promising Drugs Under Review, Funds a Concern

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

MRK : 88.85 (+0.11%)
SNY : 46.03 (-0.11%)
REGN : 372.26 (+1.06%)
ESPR : 49.96 (+6.30%)
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths

Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3

REGN : 372.26 (+1.06%)
Regeneron Pharm Set to Possibly Pullback After Yesterday's Rally of 1.52%

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $364.62 to a high of $369.63. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

REGN : 372.26 (+1.06%)
Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award

Columbia's highest honor bestowed for Yancopoulos' contributions to science and medicine

REGN : 372.26 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 376.86
1st Resistance Point 374.56
Last Price 372.26
1st Support Level 369.13
2nd Support Level 366.00

See More

52-Week High 442.00
Fibonacci 61.8% 376.82
Last Price 372.26
Fibonacci 50% 356.68
Fibonacci 38.2% 336.55
52-Week Low 271.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar